Triple-Threat attack on tough colon cancer before surgery
NCT ID NCT06791512
Summary
This study is testing if adding two drugs (an immunotherapy called a PD-1 antibody and a drug called bevacizumab) to standard chemotherapy before surgery works better than chemotherapy alone for people with a specific type of locally advanced colon or rectal cancer. The goal is to shrink tumors more effectively to make surgery more successful, lower the chance of the cancer coming back, and improve survival. About 166 participants will be randomly assigned to receive either the three-drug combination or just the standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.